We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

3281:TSEGLP J-REIT Analysis

Data as of 2026-06-05 - not real-time

₩14,940.00

Latest Price

8/10Risk

Risk Level: High

Executive Summary

Lunit Inc. is trading well below its key moving averages (price 14940 KRW vs SMA‑20 17467, SMA‑50 17890, SMA‑200 18638) and the RSI of 34.6 signals a lingering oversold condition, yet the MACD remains bearish with a widening negative histogram. Technical momentum is decidedly negative, reinforced by a 30‑day volatility of 67% and a bearish trend direction. On the fundamentals side, the company posts steep revenue growth of 24.7% but suffers from deep operating losses (‑56.8% operating margin) and a massive net cash outflow (‑51.3 B KRW operating cash flow). Its balance sheet is strained with a debt‑to‑equity ratio of 118.5 and total debt more than three times its cash reserves, driving a high max drawdown of ‑44.5%. Valuation metrics are out of line – the forward P/E is ‑17.7 and the price‑to‑sales ratio sits at 12.6, while analysts target a mean price of 12 000 KRW, indicating a substantial downside of roughly 20% from current levels. The market sentiment is in “Extreme Greed” mode (Fear‑Greed Index 93.9), which may be inflating the price despite the weak fundamentals. Overall, the combination of bearish technicals, deteriorating cash generation, and elevated leverage suggests caution, with the current price likely unsustainable without a clear turnaround.

Market Outlook

Short Term

< 1 year
Cautious
Model confidence: 8/10

Key Factors

  • Bearish technicals (price below SMA20/50/200 and negative MACD)
  • Negative earnings, cash flow and high leverage
  • Target price (12,000 KRW) well below current market

Medium Term

1–3 years
Neutral
Model confidence: 5/10

Key Factors

  • Strategic collaborations with AstraZeneca, Agilent and Daiichi Sankyo
  • Revenue growth despite ongoing losses
  • Debt burden may limit near‑term upside

Long Term

> 3 years
Positive
Model confidence: 6/10

Key Factors

  • Long‑term AI‑driven healthcare adoption trend
  • Strong R&D pipeline and partnership ecosystem
  • Current valuation discount relative to industry averages

Key Metrics & Analysis

Technical Analysis

TrendBearish
RSI34.6
Support₩14,710.00
Resistance₩22,650.00
MA 20₩17,467.00
MA 50₩17,889.80
MA 200₩18,637.51
MACDBearish
VolumeIncreasing
Fear & Greed Index93.93

Risk Assessment

Beta0.03
Volatility67.37%
Sector RiskHigh
Reg. RiskMedium
Geo RiskMedium
Currency RiskMedium
Liquidity RiskMedium

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.